The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity

Jeffrey Rubens(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Antoinette Price(Johns Hopkins University), Sabrina Wang(Johns Hopkins Medicine), Sariah J. Allen(St. Jude Children's Research Hospital), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center), Melanie Weingart(Sidney Kimmel Comprehensive Cancer Center), Brent A. Orr(St. Jude Children's Research Hospital)
Neuro-Oncology
April 5, 2017
Cited by 23


Related Papers